CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Phase 3

Not yet recruiting

Conditions: Congenital Hemophilia A

Interventions: Biological: Recombinant single-chain factor VIII (rVIII-SingleChain)

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: CSL Behring

Target Recruit Count: 60

Registration Number: NCT06738485

Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Vamifeport PR2
Drug: Vamifeport IRF
Drug: Vamifeport PR1

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT06726863

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Phase 2

Not yet recruiting

Conditions: Sickle Cell Disease Vaso-occlusive Crisis

Interventions: Biological: CSL889
Drug: Placebo

First Posted Date: 2024-11-21

Last Posted Date: 2024-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 260

Registration Number: NCT06699849

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Phase 3

Recruiting

Conditions: Acquired Fibrinogen Deficiency

Interventions: Biological: CSL511 Fibrinogen concentrate (human)
Biological: Cryoprecipitate

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-31

Lead Sponsor: CSL Behring

Target Recruit Count: 90

Registration Number: NCT06617897

Locations: 🇬🇧
Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Phase 3

Recruiting

Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome

Interventions: Biological: Placebo
Biological: IgPro20

First Posted Date: 2024-07-29

Last Posted Date: 2024-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 177

Registration Number: NCT06524739

Locations: 🇺🇸
University of Alabama Hospital at Birmingham, Birmingham, Alabama, United States
🇺🇸
Center for Complex Neurology, EDS & POTS, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States

and more 24 locations

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

Phase 3

Recruiting

Conditions: Hemophilia B

Interventions: Biological: Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)

First Posted Date: 2024-05-03

Last Posted Date: 2025-01-09

Lead Sponsor: CSL Behring

Target Recruit Count: 23

Registration Number: NCT06399289

Locations: 🇨🇳
Beijing Children's Hospital, Beijing, Beijing, China
🇨🇳
Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

and more 4 locations

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Recruiting

Conditions: Hemophilia B

Interventions: Biological: Factor IX (FIX)
Genetic: HEMGENIX

First Posted Date: 2023-08-24

Last Posted Date: 2024-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 500

Registration Number: NCT06008938

Locations: 🇺🇸
American Thrombosis and Hemostasis Network, Rochester, New York, United States

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Phase 3

Recruiting

Conditions: Hemophilia B

Interventions: Genetic: CSL222 (AAV5-hFIXco-Padua)

First Posted Date: 2023-08-22

Last Posted Date: 2024-12-19

Lead Sponsor: CSL Behring

Target Recruit Count: 35

Registration Number: NCT06003387

Locations: 🇦🇺
Royal Brisbane Hospital - 03600045, Herston, Queensland, Australia
🇦🇺
Royal Prince Alfred Hospital - 03600044, Camperdown, New South Wales, Australia
🇺🇸
University of Michigan - 84000285, Ann Arbor, Michigan, United States

and more 8 locations

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIXco-Padua

First Posted Date: 2023-07-27

Last Posted Date: 2025-01-07

Lead Sponsor: CSL Behring

Target Recruit Count: 56

Registration Number: NCT05962398

Locations: 🇺🇸
10-25 University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
10-16 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
10-20 Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 17 locations

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Phase 1

Recruiting

Conditions: Disease Driven by Complement Activation

Interventions: Drug: CSL040
Drug: Placebo

First Posted Date: 2023-07-10

Last Posted Date: 2024-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 60

Registration Number: NCT05937581

Locations: 🇦🇺
Nucleus Network Pty Ltd, Herston, Queensland, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy